All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Endothelial dysfunction is a frequent characteristic of early atherogenesis.\[[@pone.0206523.ref001], [@pone.0206523.ref002]\] Flow-mediated dilatation (FMD) has been the most widely used non-invasive method of assessing endothelial function. It reflects the bioavailability of endothelial-derived nitric oxide (NO),\[[@pone.0206523.ref003]\] and impaired FMD is associated with cardiovascular disease (CVD) events.\[[@pone.0206523.ref004], [@pone.0206523.ref005]\] FMD is, however, operator dependent and requires strict technical and methodological standardization.\[[@pone.0206523.ref006]\] Perhaps overcoming these limitations is a device that applies peripheral arterial tonometry (PAT), EndoPAT (Itamar Medical Ltd, Caesarea, Israel). EndoPAT requires less training and is largely automated. Sensors placed on each index finger measure changes in blood volume in the vasculature before and after a 5-minute occlusion of the brachial artery in the non-dominant arm. The contralateral arm serves as a control, facilitating adjustment for non-endothelial dependent factors. The adjusted post-occlusion to pre-occlusion ratio, the reactive hyperemia index (RHI), is calculated. RHI has been shown to correlate well with invasive measurement of coronary endothelial function,\[[@pone.0206523.ref007]\] predict adverse cardiovascular events in a 7-year follow-up study\[[@pone.0206523.ref008]\] and was associated with conventional risk factors in a community-based cohort of adults.\[[@pone.0206523.ref009]\] As with FMD, changes in RHI are also largely mediated by NO.\[[@pone.0206523.ref010]\] Despite this, a majority of studies show a poor correlation between FMD and RHI, suggesting that they provide different and unique information about vasoreactivity.\[[@pone.0206523.ref011]--[@pone.0206523.ref016]\]

Patients with type 1 diabetes (T1D) are prone to accelerated atherosclerosis, leading to increased morbidity and mortality from CVD.\[[@pone.0206523.ref017], [@pone.0206523.ref018]\] There is, however, insufficient knowledge about the early phases of atherosclerosis, partially due to the lack of clinically useful non-invasive techniques to precisely assess the subclinical stage. Endothelial function is frequently impaired in adult patients with T1D.\[[@pone.0206523.ref019]\] In children and adolescents with T1D, most, but not all studies of FMD have demonstrated reduced endothelial function in patients with T1D compared with healthy control subjects.\[[@pone.0206523.ref020]--[@pone.0206523.ref024]\] Studies applying RHI in this age group have also largely shown reduced values in patients with T1D.\[[@pone.0206523.ref025]--[@pone.0206523.ref027]\] None of these studies were longitudinal.

We hypothesized that T1D would negatively affect endothelial function. We aimed to test our hypothesis by assessing the impact of T1D on endothelial function as detected by PAT and its relationship with cardiovascular risk factors and long term glycemic control.

Materials and methods {#sec006}
=====================

Study population {#sec007}
----------------

The baseline examinations in the population-based \"Atherosclerosis and Childhood Diabetes\" study were performed from 2006--2008.\[[@pone.0206523.ref028]\] As part of the 5-year follow-up, 2011--2013, participants above 18 years of age were invited to take part in the present sub-study. Among the healthy control subjects, 17 had baseline values and 15 were recruited in the 5-year follow-up. In order to isolate the effect of T1D in early atherosclerosis, exclusion criteria were smoking, pregnancy, current infectious disease, hypertension (above 90th percentile), chronic diseases other than diabetes or any kind of long term medication. The diabetes patients all received intensified insulin injection treatment (\> 4 daily injections) or used insulin pumps from the time of diagnosis. None had overt retinopathy or nephropathy. A total of 46 diabetes patients and 32 controls were included. They all gave their written informed consent. The protocol was approved by the Norwegian Regional Committee for Research Ethics, and the study was conducted according to the Declaration of Helsinki.

Laboratory analyses {#sec008}
-------------------

All examinations were performed after an overnight fast. The baseline clinical examination has been described previously,\[[@pone.0206523.ref028]\] and baseline data was available for all diabetes patients and 17 of the controls.

Annual HbA1c values from 2000 to 2012 were obtained from the Norwegian Childhood Diabetes Registry, and they were all measured at the same DCCT-standardized laboratory using high performance liquid chromatography (Variant; Bio-Rad, Richmond, CA, USA), the inter-assay coefficient of variation (CV) \< 3%. Each patient had on average 8 annual HbA1c measurements (range 3--12), and these were used to calculate mean HbA1c at baseline and follow-up. Diabetes duration multiplied by mean HbA1c at each time point provided an estimate of glycemic burden.

Routine laboratory analyses were performed by conventional methods.

Endothelial function {#sec009}
--------------------

Digital PAT was performed using EndoPAT 2000 (Itamar Medical Ltd, Caesarea, Israel) as part of the 5-year follow-up of the \"Atherosclerosis and Childhood Diabetes\" study. The patients were examined in the supine position on a bed in a quiet and dimly lit room. Plethysmographic bio-sensors were placed on the index finger of both hands. From these, arterial pulsatile volume changes were recorded. After registering a five minute baseline signal, a brachial blood pressure cuff on the non-dominant upper arm was inflated to approximately 200 mmHg for exactly five minutes. This period of ischemia resulted in vasodilation followed by reactive hyperemia when blood flow returned. The PAT signal was recorded for another five minutes. A post-occlusion to pre-occlusion ratio was calculated by the EndoPAT software, resulting in a reactive hyperemia index. An RHI score of 1.67 and below is considered abnormal, and a score above 2.00 is recommended.\[[@pone.0206523.ref007]\]

Statistical analysis {#sec010}
--------------------

Demographic and clinical data are presented as either proportions, means with their standard deviations (SD) or medians with the 25th and 75th percentile. Differences in continuous variables between groups were tested with the Student *t*-test for normally distributed data, alternatively the Mann-Whitney *U*-test for non-normally distributed data. Correlation analyses between continuous variables were performed using Pearson's correlation coefficient (r) or Spearman's rho (*ρ*) when appropriate. Univariate linear regression analysis was performed to study the association between current conventional risk factors (systolic blood pressure, diastolic blood pressure, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoprotein B, apolipoprotein A-I, HbA1c, waist circumference, body mass index (BMI) and diabetes duration) as exposure variables with RHI as the outcome variable. To identify possible confounders, we studied all variables that could influence the outcome. Only variables with significant relationships with both the exposure and the outcome variables were considered as possible confounders and included in a multivariate analysis. Adjustment for multiple confounding factors was done using multivariate linear regression analysis with a manual backward elimination procedure. A significance level of 5% was used. All statistical analyses were performed using the SPSS software package for Mac, version 19.0 (SPSS, Chicago, IL).

Results {#sec011}
=======

The clinical and metabolic characteristics of the participants are shown in [Table 1](#pone.0206523.t001){ref-type="table"}. The diabetes patients had greater waist circumference compared with the controls, as well as higher HbA1c and apolipoprotein B. At baseline they also had higher BMI, total cholesterol, LDL cholesterol and apolipoprotein A-I. The participants in both groups had otherwise similar characteristics.

10.1371/journal.pone.0206523.t001

###### Clinical and metabolic characteristics.

![](pone.0206523.t001){#pone.0206523.t001g}

                                                                             Baseline            5-year follow-up                                                      
  -------------------------------------------------------------------------- ------------------- ------------------- --------- ------------------- ------------------- ---------
  n                                                                          46                  17                            46                  32                  
  Diabetes duration (years)[^1^](#t001fn002){ref-type="table-fn"}            5.3 (3.4, 9.6)                                    10.0 (8.1, 14.3)                        
  Insulin pump users n (%)                                                   20 (43.5)                                         23 (50.0)                               
  Age (years)                                                                16.0 (1.8)          15.4 (2.0)          .286      20.8 (1.8)          21.1 (1.9)          .519
  Girls, n (%)                                                               22 (47.8)           9 (52.9)            .718      22 (47.8)           17 (53.1)           .645
  Height (cm)                                                                170.4 (8.9)         170.3 (7.8)         .940      174.5 (8.5)         175.3 (9.1)         .688
  Weight (kg)                                                                66.5 (15.0)         59.0 (12.2)         .070      78.8 (15.3)         72.6 (15.0)         .080
  BMI (kg/m^2^)[^1^](#t001fn002){ref-type="table-fn"}                        21.6 (19.6, 25.4)   19.0 (17.9, 23.7)   .017      23.9 (22.6, 28.1)   22.7 (20.5, 26.0)   .037
  Waist circumference (cm)                                                   76.5 (9.8)          69.5 (6.4)          .003      84.1 (10.5)         78.0 (10.1)         .012
  Systolic blood pressure (mmHg)                                             105.2 (11.0)        104.6 (10.8)        .866      115.8 (11.5)        114.6 (8.9)         .616
  Diastolic blood pressure (mmHg)                                            62.2 (9.6)          60.5 (6.2)          .520      70.0 (8.9)          69.9 (7.4)          .943
  Pulse pressure                                                             43.0 (7.6)          44.1 (9.3)          .631      45.7 (9.2)          44.7 (8.9)          .605
  HbA1c (%)                                                                  8.2 (1.1)           5.3 (0.3)           \< .001   8.7 (1.4)           5.2 (0.3)           \< .001
  Mean HbA1c (%)                                                             7.9 (1.1)                                         8.3 (1.0)                               
  Glycemic burden (% x years)                                                52.3 (34.9)                                       94.0 (36.3)                             
  Total cholesterol (mmol/L)                                                 4.5 (0.7)           4.0 (0.7)           .014      4.8 (1.0)           4.5 (0.9)           .138
  HDL cholesterol (mmol/L)                                                   1.7 (0.4)           1.6 (0.4)           .325      1.6 (0.4)           1.6 (0.5)           .914
  LDL cholesterol (mmol/L)                                                   2.5 (0.6)           2.1 (0.6)           .042      2.7 (0.8)           2.5 (0.7)           .150
  Triglycerides (mmol/L)[^1^](#t001fn002){ref-type="table-fn"}               0.7 (0.6, 0.8)      0.6 (0.4, 0.7)      .248      1.0 (0.7, 1.4)      1.0 (0.7, 1.5)      .681
  Apolipoprotein B (g/L)                                                     0.74 (0.16)         0.60 (0.13)         .002      0.92 (0.23)         0.81 (0.20)         .041
  Apolipoprotein A-I (g/L)                                                   1.44 (0.24)         1.18 (0.38)         .021      1.56 (0.32)         1.55 (0.35)         .936
  Urine Albumin/Creatinine (mg/mmol)[^1^](#t001fn002){ref-type="table-fn"}   0.50 (0.30, 1.28)   0.77 (0.35, 1.64)   .669      0.56 (0.24, 1.25)   0.30 (0.14, 0.99)   .405
  Reactive Hyperemia Index (RHI)                                                                                               2.00 (0.59)         2.21 (0.56)         .116

Mean values (SD).

^1^ Median (25th and 75th percentile).

RHI tended to be lower in the diabetes group compared with controls, but the difference was not significant, mean 2.00 (SD = 0.59) vs. 2.21 (SD = 0.56), p = .116. We found no significant difference between the genders among all participants (mean girls 2.08 (SD = 0.60) vs. boys 2.09 (SD = 0.57), p = .929), in the diabetes group (mean girls 2.01 (SD = 0.59) vs. boys 1.99 (SD = 0.61), p = .888), or in the control group (mean girls 2.17 (SD = 0.62) vs. boys 2.26 (SD = 0.49), p = .646). There was no significant correlation between RHI and HbA1c, mean HbA1c or glycemic burden, either at baseline or at the 5-year follow-up. RHI was not significantly associated with any current conventional cardiovascular risk factors in either group. Using the cut-off value recommended by the manufacturer of 1.67 to determine endothelial dysfunction, we found no significant difference between the groups, p = .447 ([Fig 1](#pone.0206523.g001){ref-type="fig"}).

![Percentage of participants above and below RHI = 1.67.](pone.0206523.g001){#pone.0206523.g001}

Discussion {#sec012}
==========

The main finding in our study was the lack of significant difference in RHI between young adult patients with T1D and healthy control subjects. This is in contrast to previous well conducted studies with similar sample size (44 and 23 patients with T1D, respectively).\[[@pone.0206523.ref025], [@pone.0206523.ref026]\] The participants in these studies, however, were slightly younger than in our study, and all had not completed puberty. Possibly, pubertal stage could explain these differences, as later studies in healthy children have shown that RHI increases during puberty.\[[@pone.0206523.ref029], [@pone.0206523.ref030]\] Difference in pubertal stage might also be the reason Mahmud et al. found lower values in boys with T1D compared with girls.\[[@pone.0206523.ref031]\] Pareyn et al., however, found lower values in girls with T1D.\[[@pone.0206523.ref027]\] This discrepancy may be due to chance, as we were unable to demonstrate any gender difference, in line with a larger study in healthy children.\[[@pone.0206523.ref032]\]

As [Fig 1](#pone.0206523.g001){ref-type="fig"} illustrates, 30.4% of the diabetes patients were below the cut-off value set by the manufacturer to indicate endothelial dysfunction. This was also the case for 21.9% of the controls, and there was no significant difference between the groups. Scaramuzza et al. have demonstrated considerably higher percentages (76.7% and 81.8%) in adolescents with T1D during one year of follow-up.\[[@pone.0206523.ref033]\] We find it unlikely that 21.9% of healthy young adults have impaired endothelial function. Thus, the relatively high number of abnormal values among both diabetes patients and control subjects suggests that the recommended cut-off value might not be ideal for cardiovascular risk assessment in this age group.

In a cross-sectional study of middle-aged healthy volunteers, associations between RHI and male gender, BMI, total-/HDL-cholesterol, diabetes, smoking and lipid-lowering therapy were reported.\[[@pone.0206523.ref009]\] Also, in healthy adolescents RHI was associated with soluble intercellular adhesion molecule-1, insulin resistance and saturated fatty acids.\[[@pone.0206523.ref032]\] Contrary to this, smaller studies in healthy subjects\[[@pone.0206523.ref015], [@pone.0206523.ref030]\] and in young patients with T1D\[[@pone.0206523.ref025], [@pone.0206523.ref027]\] only showed significant associations with RHI and pubertal stage. In our study, there were no significant associations between traditional cardiovascular risk factors and RHI in either group. These disparities are likely due to differences in sample size.

Previous studies are also inconsistent with regard to the association between RHI and HbA1c.\[[@pone.0206523.ref025]--[@pone.0206523.ref027], [@pone.0206523.ref031], [@pone.0206523.ref033], [@pone.0206523.ref034]\] The present study provides reliable longitudinal assessments of HbA1c, in many cases annually since diagnosis. The resulting measure of glycemic burden, however, was not associated with RHI.

Inherent strengths of this study include the prospective design and several longitudinal measurements of HbA1c for each patient. Major limitations are the small number of study subjects, particularly controls with baseline values, and the lack of serial measurements of RHI.

In conclusion, we did not find reduced endothelial function, as measured by EndoPAT, in young adults with T1D compared with healthy controls. Furthermore, we did not find any gender difference or significant associations with traditional cardiovascular risk factors or glycemic burden. These results suggest that EndoPAT has limited value in CVD risk assessment in young adults with T1D, but larger and longitudinal studies are needed.

Supporting information {#sec013}
======================

###### Dataset for endothelial function.

(XLSX)

###### 

Click here for additional data file.
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